227 related articles for article (PubMed ID: 33962331)
1. Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume.
Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Grau-Rivera O; Operto G; Gispert JD; Vilor-Tejedor N; Sala-Vila A; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Molinuevo JL;
Neurobiol Aging; 2021 Aug; 104():24-31. PubMed ID: 33962331
[TBL] [Abstract][Full Text] [Related]
2. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum.
Allison SL; Koscik RL; Cary RP; Jonaitis EM; Rowley HA; Chin NA; Zetterberg H; Blennow K; Carlsson CM; Asthana S; Bendlin BB; Johnson SC
Neuroimage Clin; 2019; 23():101895. PubMed ID: 31252287
[TBL] [Abstract][Full Text] [Related]
4. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
[TBL] [Abstract][Full Text] [Related]
5. Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Wen C; Bi YL; Hu H; Huang SY; Ma YH; Hu HY; Tan L; Yu JT
J Alzheimers Dis; 2022; 85(3):1143-1151. PubMed ID: 34924386
[TBL] [Abstract][Full Text] [Related]
6. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
Pereira JB; Westman E; Hansson O;
Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
[TBL] [Abstract][Full Text] [Related]
7. Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline.
Ebenau JL; Pelkmans W; Verberk IMW; Verfaillie SCJ; van den Bosch KA; van Leeuwenstijn M; Collij LE; Scheltens P; Prins ND; Barkhof F; van Berckel BNM; Teunissen CE; van der Flier WM
Neurology; 2022 Mar; 98(13):e1315-e1326. PubMed ID: 35110378
[TBL] [Abstract][Full Text] [Related]
8. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
9. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
Huang Y; Li Y; Xie F; Guo Q
CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
[TBL] [Abstract][Full Text] [Related]
10. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
Zetterberg H; Skillbäck T; Mattsson N; Trojanowski JQ; Portelius E; Shaw LM; Weiner MW; Blennow K;
JAMA Neurol; 2016 Jan; 73(1):60-7. PubMed ID: 26524180
[TBL] [Abstract][Full Text] [Related]
11. Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study.
Rådestig MA; Skoog J; Zetterberg H; Skillbäck T; Zettergren A; Sterner TR; Fässberg MM; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
J Alzheimers Dis; 2023; 91(1):291-303. PubMed ID: 36617786
[TBL] [Abstract][Full Text] [Related]
12. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
13. CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults.
Idland AV; Sala-Llonch R; Borza T; Watne LO; Wyller TB; Brækhus A; Zetterberg H; Blennow K; Walhovd KB; Fjell AM
Neurobiol Aging; 2017 Jan; 49():138-144. PubMed ID: 27794264
[TBL] [Abstract][Full Text] [Related]
14. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment.
Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM
JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
[TBL] [Abstract][Full Text] [Related]
16. Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy.
Svenningsson AL; Stomrud E; Palmqvist S; Hansson O; Ossenkoppele R
Alzheimers Res Ther; 2022 Oct; 14(1):144. PubMed ID: 36192766
[TBL] [Abstract][Full Text] [Related]
17. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
18. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
[TBL] [Abstract][Full Text] [Related]
19. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
[TBL] [Abstract][Full Text] [Related]
20. Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid-β Levels.
Valech N; Sánchez-Benavides G; Tort-Merino A; Coll-Padrós N; Olives J; León M; Falcon C; Molinuevo JL; Rami L
J Alzheimers Dis; 2019; 72(4):1287-1302. PubMed ID: 31707366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
